Austin, Texas, November 2, 2022 /PRNewswire/ — Natera, Inc. NTRAa global leader in cell-free DNA (cfDNA) testing, announced today that it has been awarded a nationwide contract effective September 15, 2022has partnered with the US Department of Veterans Affairs (VA) National Precision Oncology Program to provide minimal residual disease (MRD) and surveillance services using the company’s personalized and tumor-informed MRD test, Signatera™.

The VA is the nation’s largest integrated healthcare system, serving over 450,000 veterans suffering from cancer.¹ Through this agreement, the Signatera™ test will be made available for mass use to detect residual disease and make difficult treatment decisions. Signatera™ is covered by Medicare for use in colon cancer, muscle-invasive bladder cancer, and pan-cancer immunotherapy surveillance, and has been validated for multiple cancer types to detect recurrence earlier than standard diagnostic tools^2.3 and to assess response to treatment in conjunction with imaging.⁴ Data demonstrating the clinical validity and usefulness of Signatera™ has been published in 35 peer-reviewed publications.

“We are proud to work with the VA to bring Signatera to our nation’s veterans,” he said Solomon Moshkevich, Managing Director of Oncology at Natera. “We look forward to working with the VA and other integrated healthcare systems across the country to integrate Signatera into standard clinical practice with the goal of improving clinical outcomes and reducing costs associated with unnecessary treatments.”

About Signatera™

Signatera™ is a custom Circulating Tumor DNA (ctDNA) test for treatment monitoring and assessment of Molecular Residual Disease (MRD) in patients previously diagnosed with cancer. The test is available for both clinical and research use and has received three Breakthrough Device Designations from the FDA for multiple cancer types and indications. The Signatera™ test is personalized and tumor-informed,…